Association between the Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma 2 and inflammatory bowel disease: A meta-analysis

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Zhang, Zhi Feng ^a   Yang, Ning ^a   Zhao, Gang ^a   Zhu, Lei ^a   Wang, Li Xia ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PROLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

AMINO ACID SUBSTITUTION; ARTICLE; CASE CONTROL STUDY; COCHRANE LIBRARY; CROHN DISEASE; DATA BASE; EAST ASIAN; ENTERITIS; ETHNIC DIFFERENCE; ETHNIC GROUP; EUROPEAN AMERICAN; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MOLECULAR PATHOLOGY; PROTECTION; RECESSIVE INHERITANCE; SINGLE NUCLEOTIDE POLYMORPHISM; TURKISH; ULCERATIVE COLITIS; ASIAN; CAUCASIAN; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; MALE; META ANALYSIS;

ASIAN CONTINENTAL ANCESTRY GROUP; CROHN DISEASE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; POLYMORPHISM, GENETIC; PPAR GAMMA;

EID: 84855995582     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030551     Document Type: Article

References (37)

1. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A, (2011) Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 140 (6): 1785-1794.
2. Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, et al. (2011) Guidelines for the management of inflammatory bowel disease in adults. Gut 60 (5): 571-607.
3. Baumgart DC, Carding SR, (2007) Inflammatory bowel disease: cause and immunobiology. Lancet 369 (9573): 1627-1640.
4. Marks DJ, (2011) Defective innate immunity in inflammatory bowel disease: a Crohn's disease exclusivity? Curr Opin Gastroenterol 27 (4): 328-334.
5. Yamamoto-Furusho JK, Peñaloza-Coronel A, Sánchez-Muñoz F, Barreto-Zuñiga R, Dominguez-Lopez A, (2011) Peroxisome proliferator-activated receptor-gamma (PPAR-γ) expression is downregulated in patients with active ulcerative colitis. Inflamm Bowel Dis 17 (2): 680-681.
6. Peyrin-Biroulet L, Beisner J, Wang G, Nuding S, Oommen ST, et al. (2010) Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proc Natl Acad Sci U S A 107 (19): 8772-8777.
7. Celinski K, Dworzanski T, Korolczuk A, Slomka M, Radej S, et al. (2011) Activated and inactivated PPARs-γ modulate experimentally induced colitis in rats. Med Sci Monit 17 (4): BR116-124.
8. Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, et al. (1997) Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun 241: 270-274.
9. Aoyagi Y, Nagata S, Kudo T, Fujii T, Wada M, et al. (2010) Peroxisome proliferator-activated receptor γ 2 mutation may cause a subset of ulcerative colitis. Pediatr Int 52 (5): 729-734.
10. Poliska S, Penyige A, Lakatos PL, Papp M, et al. and the Hungarian IBD Study Group (2011) Association of peroxisome proliferator-activated receptor gamma polymorphisms with inflammatory bowel disease in a hungarian cohort. Inflamm Bowel Dis. 30 Available: http://onlinelibrary.wiley.com/doi/10.1002/ibd.21798/pdf. Accessed 2011 June.
11. Shrestha UK, Karimi O, Crusius JB, Zhou F, Wang Z, et al. (2010) Distribution of peroxisome proliferator-activated receptor-gamma polymorphisms in Chinese and Dutch patients with inflammatory bowel disease. Inflamm Bowel Dis 16 (2): 312-319.
12. Higgins JPT, Green S, eds, (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Accessed 2011 June 30.
13. Dear K, Begg C, (1992) An approach to assessing publication bias prior to performing a meta-analysis. Stat Sci 7: 237-245.
14. Sterne JA, Egger M, (2001) Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 54: 1046-1055.
15. Holm S, (1979) A Simple Sequentially Rejective Bonferroni Test Procedure. Scand J Stat 6: 65-70.
16. Xin XY, Ding JQ, Chen SD, (2010) Apolipoprotein E promoter polymorphisms and risk of Alzheimer's disease: evidence from meta-analysis. J Alzheimers Dis 19 (4): 1283-1294.
17. Lehmann DJ, Cortina-Borja M, Warden DR, Smith AD, Sleegers K, et al. (2005) Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer's disease. Am J Epidemiol 162: 305-317.
18. Atug O, Tahan V, Eren F, Tiftikci A, Imeryuz N, et al. (2008) Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma (PPARgamma) gene in inflammatory bowel disease. J Gastrointestin Liver Dis 17 (4): 433-437.
19. Wang F, Tahara T, Arisawa T, Sakata M, Takahama K, et al. (2008) Polymorphism of peroxisome proliferator-activated receptor gamma is not associated to Japanese ulcerative colitis. Hepatogastroenterology 55 (81): 73-75.
20. Ferreira P, Cravo M, Guerreiro CS, Tavares L, Santos PM, et al. (2010) Fat intake interacts with polymorphisms of Caspase9, FasLigand and PPARgamma apoptotic genes in modulating Crohn's disease activity. Clin Nutr 29 (6): 819-823.
21. Andersen V, Christensen J, Ernst A, Jacobsen BA, Tjønneland A, et al. (2011) Polymorphisms in NF-κB, PXR, LXR, PPARγ and risk of inflammatory bowel disease. World J Gastroenterol 17 (2): 197-206.
22. Salim SY, Söderholm JD, (2011) Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis 17 (1): 362-381.
23. Becker CE, O'Neill LA, (2007) Inflammasomes in inflammatory disorders: the role of TLRs and their interactions with NLRs. Semin Immunopatho 29: 239-248.
24. Genolet R, Wahli W, Michalik L, (2004) PPARs as drug targets to modulate inflammatory responses? Curr Drug Targets Inflamm Allergy 3: 361-375.
25. Reynolds CM, Draper E, Keogh B, Rahman A, Moloney AP, et al. (2009) A conjugated linoleic acid-enriched beef diet attenuates lipopolysaccharide-induced inflammation in mice in part through PPARgamma-mediated suppression of toll-like receptor 4. J Nutr 139 (12): 2351-2357.
26. Dubuquoy L, Jansson EA, Deeb S, Rakotobe S, Karoui M, et al. (2003) Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology 124: 1265-1276.
27. Lewis JD, Lichtenstein GR, Deren JJ, Sands BE, Hanauer SB, (2008) Rosiglitazone for Ulcerative Colitis Study Group. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology 134 (3): 688-695.
28. Masugi J, Tamori Y, Mori H, Koike T, Kasuga M, (2000) Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun 268: 178-182.
29. Marks DJ, Harbord MW, MacAllister R, Rahman FZ, Young J, et al. (2006) Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet 367: 668-678.
30. Smith AM, Rahman FZ, Hayee B, Graham SJ, Marks DJ, et al. (2009) Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease. J Exp Med 206: 1883-1897.
31. Magalhaes JG, Sorbara MT, Girardin SE, Philpott DJ, (2011) What is new with Nods? Curr Opin Immunol 23: 29-34.
32. Vind I, Jespersgaard C, Hougs L, Riis L, Dinesen L, et al. (2005) Genetic and environmental factors in monozygotic twins with Crohn's disease and their first-degree relatives: a case report. Digestion 1: 262-265.
33. Jess T, Riis L, Jespersgaard C, Hougs L, Andersen PS, et al. (2005) Disease concordance, zygosity, and NOD2/CARD15 status: follow-up of a population-based cohort of Danish twins with inflammatory bowel disease. Am J Gastroenterol 100: 2486-2492.
34. Torok HP, Glas J, Lohse P, Folwaczny C, (2003) Alterations of the CARD15/NOD2 gene and the impact on management and treatment of Crohn's disease patients. Dig Dis 21: 339-345.
35. Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, et al. (2010) Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 42: 1118-1125.
36. Leong RW, Armuzzi A, Ahmad T, Wong ML, Tse P, et al. (2003) NOD2/CARD15 gene polymorphisms and Crohn's disease in the Chinese population. Aliment Pharmacol Ther 1: 1465-1470.
37. Inoue N, Tamura K, Kinouchi Y, Fukuda Y, Takahashi S, et al. (2002) Lack of common NOD2 variants in Japanese patients with Crohn's disease. Gastroenterology 123: 86-91.